Davies, Melanie J <br/><br/>
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.  [electronic resource] 

 -  Diabetes, obesity & metabolism  12 2017 
 - 1798-1804 p.  digital 
<br/><br/> Publication Type: Comparative Study; Equivalence Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12980  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Body Mass Index<br/>Diabetes Mellitus, Type 2--complications<br/>Disease Progression<br/>Drug Combinations<br/>Drug Resistance<br/>Drug Therapy, Combination--adverse effects<br/>Glucagon-Like Peptide-1 Receptor--metabolism<br/>Glycated Hemoglobin--analysis<br/>Humans<br/>Hyperglycemia--prevention & control<br/>Hypoglycemia--chemically induced<br/>Insulin Glargine--administration & dosage<br/>Middle Aged<br/>Obesity--complications<br/>Peptides--administration & dosage<br/>Postprandial Period<br/>Weight Gain--drug effects<br/>Glucagon-Like Peptide-1 Receptor Agonists